Brochure
27 Aug 2026
PharmExtracta Product Portfolio 2026
PDF 985 kB
Discover PharmExtracta’s 2026 product portfolio, featuring clinically supported and innovative solutions across Precision Bacterial Care, botanical products, precision prebiotics and biomolecular supplements. The brochure provides an overview of our products, targeted health areas, biopharmaceutical compositions, formulation technologies and directions for use, highlighting PharmExtracta’s science-driven approach to product development.
Content provided by our supplier
PHARMEXTRACTA S.P.A.
-
Country/Region:Italy
-
On CPHI since:2020
-
Employees:100 - 249
Company types
Other Content from PHARMEXTRACTA S.P.A. (3)
-
News PharmExtracta launches Gabapral® Drops with Bifidobacterium adolescentis PRL2019®
PharmExtracta expands the Gabapral® range with a new oil-based drops formulation containing Bifidobacterium adolescentis PRL2019®, a precision probiotic strain selected for its GABA-producing capacity. The new 20 ml format provides a convenient option for daily probiotic supplementation. -
Brochure PharmExtracta – Top Therapeutic Areas & Medical Devices 2026
Explore PharmExtracta’s key therapeutic areas and discover our portfolio of probiotics, botanicals, micronutrients and medical devices. This concise overview maps our product solutions across major health areas and provides dedicated insights into selected medical devices for ENT and women’s health applications. -
Datasheet PharmExtracta – Company Profile 2026
An overview of PharmExtracta, its scientific approach, business model, market presence and product portfolio, highlighting the company’s expertise in developing and bringing evidence-based healthcare solutions to market.